Cystic Fibrosis and the SARS-CoV-2 Virus: A Review

Authors

Lorena Orozco Laboratorio de Inmunogenómica y enfermedades metabólicas, Instituto Nacional de Medicina Genómica, Periferico Sur 4809, Arenal Tepepan, Tlalpan, 14610 Ciudad de México, México https://orcid.org/0000-0002-1250-1203
Angélica Martínez-Hernández Laboratorio de Inmunogenómica y enfermedades metabólicas, Instituto Nacional de Medicina Genómica, Ciudad de México, México https://orcid.org/0000-0001-9883-2988

DOI:

https://doi.org/10.31644/RMI.V4N5.2024.A11

Keywords:

ACE Gene, COVID-19, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), TMPRSS2 Gene

Abstract

Cystic fibrosis (CF) is a recessive autosomal disease that affects ion transport, causing abnormalities in ducts and secretory organs such as the respiratory and gastrointestinal tracts. Because CF is associated with respiratory insufficiency and lung damage, a higher susceptibility was expected in CF patients at the onset of the COVID-19 pandemic. However, several studies showed lower infection rates compared to the general population. This review describes the fundamental concepts of CF and SARS-CoV-2, and discusses the beneficial and adverse effects observed in CF patients with COVID-19.

Downloads

Download data is not yet available.

References

Abolhasani FS, Moein M, Rezaie N, Sheikhimehrabadi P, Shafiei M, Afkhami H, Modaresi M (2024). Occurrence of COVID-19 in cystic fibrosis patients: a review. Front Microbiol. 15:1356926 https://doi.org/10.3389/fmicb.2024.1356926

Al Yazidi L., Al Maskari N. & Al Reesi M. (2021). Children with cystic fibrosis hospitalized with COVID-19: multicentre experience. J Paediatric Child Health, 57(5): 767-768. https://doi.org/10.1111/jpc.15495

Almughem F., Aldossary A., Tawfik E., Alomary M., Alharbi W., Alshahrani M. & Alshehri A. (2020). Cystic fibrosis: overview of the current development trends and innovative therapeutic strategies. Pharmaceutics, 12(7): 616. https://doi.org/0.3390/pharmaceutics12070616

Bai C., Zhong Q. & Gao GF. (2022). Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci. Feb;65(2):280-294. https://doi.org/10.1007/s11427-021-1964-4.

Bain R., Cosgriff R., Zampoli M., Elbert A., Burgel P., Carr S., Castaños C., Colombo C., Corvol H., Faro A., et al. (2021). Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. J Cyst Fibros, 20(1):25–30. https://doi.org/10.1016/j.jcf.2020.11.021

Betapudi B., Aleem A. & Kothadia J. (2022). Cystic Fibrosis And Liver Disease. NCBI StatPearls https://www.ncbi.nlm.nih.gov/books/NBK556086/

Bezzerri V., Lucca F., Volpi S. & Cipolli M. (2020). Does cystic fibrosis constitute an advantage in COVID-19 infection?. Ital J Pediatr, 46(1): 143. https://doi.org/10.1186/s13052-020-00909-1

CDC (2019). COVID-19 People with Certain Medical Conditions. Centers for Disease Control and Prevention https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html

Cosgriff R., Ahern S., Bell S., Brownlee K., Burgel P., Byrnes C., Corvol H., Cheng S., Elbert A., et al. Global Registry Harmonization Group (2020). A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros, 19(3): 355–358. https://doi.org/10.1016/j.jcf.2020.04.012

Cystic Fibrosis Foundation (2024) The Clinical and Functional Translation of CFTR (CFTR2) (http://www.cftr2.org/mutations_history)

Doumit M., Chuang S., Middleton P., Selvadurai H., Sivam S., Ruseckaite R., Ahern S., Mallitt K. A., Pacey V., Gray K. & Jaffe A. (2023). Clinical outcomes of adults and children with cystic fibrosis during the COVID-19 pandemic. Journal of Cystic Fibrosis, 22(3). https://doi.org/10.1016/j.jcf.2022.09.006

Driscoll S., Carroll W., Nichani S., Fishwick R., Bakewell K. & Gilchrist, F. (2022). COVID-19 infection and nocardiosis causing the death of an adolescent with cystic fibrosis. Pediatr Pulmonol, 10.1002/ppul.25954. https://doi.org/10.1002/ppul.25954

Endres T. & Konstan M. (2022). What Is Cystic Fibrosis? JAMA Jan 11;327(2):191. https://doi.org/10.1001/jama.2021.23280 PMID: 35015036

Fainardi V., Longo F., Chetta A., Esposito S., & Pisi G. (2020). Sars-CoV-2 infection in patients with cystic fibrosis. An overview. Acta Biomed, 91(3): e2020035. https://doi.org/10.23750/abm.v91i3.10391

Jackson C., Farzan M., Chen B. & Choe H. (2022). Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol, 23(1): 3–20. https://doi.org/10.1038/s41580-021-00418-x

Jaudszus A., Pavlova M., Rasche M., Baier M., Moeser A. & Lorenz, M. (2022). One year monitoring of SARS-CoV-2 prevalence in a German cohort of patients with cystic fibrosis. BMC pulmonary medicine, 22(1), 101. https://doi.org/10.1186/s12890-022-01900-8

Lotti V., Merigo F., Lagni A., Di Clemente A., Ligozzi M., Bernardi P., Rossini G., Concia E., Plebani R., Romano M., Sbarbati A., Sorio C., & Gibellini D. (2022). CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial Cells. Cells, 11(8), 1347. https://doi.org/10.3390/cells11081347

Martínez-Hernández A, Mendoza-Caamal EC, Mendiola-Vidal NG, Barajas-Olmos F, Villafan-Bernal JR, et al. (2024). CFTR pathogenic variants spectrum in a cohort of Mexican patients with cystic fibrosis. Heliyon, 10(7):e28984. https://doi.org/10.1016/j.heliyon.2024.e28984

Mathew H., Choi M., Parkins M. & Fritzler M. (2021). Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med, 21(1): 173.https://doi.org/10.1186/s12890-021-01528-0

Moola F., Ross T., Buliung R., Neville A. & Hong S. (2024) We are Always in Self-Isolation”: Navigating COVID-19 as a Young Person in Canada with Cystic Fibrosis, Wellbeing, Space and Society (2024), doi: https://doi.org/10.1016/j.wss.2024.100202

Naehrlich L., Orenti A., Dunlevy F., Kasmi I., Harutyunyan S., Pfleger A., Keega S., Daneau G., Petrova G., Tješić-Drinković et al. (2021). Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. J Cyst Fibros, 20(4): 566–577. https://doi.org/10.1016/j.jcf.2021.03.017

Orozco L., Chávez M., Saldaña Y., Velázquez R., Carnevale A., González-del Ángel A. & Jiménez S. (2006). Fibrosis quística: la frontera del conocimiento molecular y sus aplicaciones clínicas. Rev Invest Clin, 58(2):139-152

O'Sullivan B. & Freedman S. (2009). Cystic fibrosis. Lancet, 373(9678): 1891–1904. https://doi.org/10.1016/S0140-6736(09)60327-5

Páez-Velásquez J., Romero-Uribe I., Castilla-Peón M., Lezana-Fernández J. & Chávez-López A. (2021). SARS-CoV-2 infection in a pediatric patient with cystic fibrosis. Bol Med Hosp Infant Mex, 78(1). https://doi.org/10.24875/bmhim.20000216

Pastrian-Soto G. (2020). Genetic and Molecular Basis of COVID-19 (SARS-CoV-2) Mechanisms of Pathogenesis and Imnune. Int. J. Odontostomat, 14(3), 331-337. http://dx.doi.org/10.4067/S0718-381X2020000300331

Peckham D., McDermott M., Savic S. & Mehta, A. (2020). COVID-19 meets cystic fibrosis: for better or worse? Genes Immun, 21(4): 260-262. https://doi.org/10.1038/s41435-020-0103-y

Ratchford T., Teckman J. & Patel D. (2018). Gastrointestinal pathophysiology and nutrition in cystic fibrosis. Expert Rev Gastroenterol Hepatol, 12(9):853–862. https://doi.org/10.1080/17474124.2018.1502663

Ruíz V., Hernández R. & de la Rosa G. (2018). Genética clínica. Manual Moderno, 2.ª ed., p. 582

Scotet V., L'Hostis C. & Férec C. (2020). The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes (basel), 11(6): 589. https://doi.org/10.3390/genes11060589

Seyedi S., Sadeghi H., Kianifar H., Hamedi A. & Saeidinia A. (2022). COVID-19 infection in an infant with cystic fibrosis: A case report and possible therapeutic effect of hypertonic saline. Clin Case Rep, 10(4), e05782. https://doi.org/10.1002/ccr3.5782

Simonson J., Esposito C., Frantzen T., Henthorne K., Espinal A., Romano S., Ramdeo R., … & Wang, J. (2022). The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York. J Cyst Fibros, 21(3), e176–e183. https://doi.org/10.1016/j.jcf.2022.02.012

Singh V. & Schwarzenberg S. (2017). Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros, Suppl 2: S70–S78. https://doi.org/10.1016/j.jcf.2017.06.011

Stanton, B. A., Hampton, T. H., & Ashare, A. (2020). SARS-CoV-2 (COVID-19) and cystic fibrosis. Am J Physiol. Lung Cell Mol Physiol, 319(3): L408–L415. https://doi.org/10.1152/ajplung.00225.2020

Tinajero Iriarte M., Lamshing Salinas P., Casaubon Garcín P. & Hernández Archundia E. (2016). Ileo meconial como primera manifestación de fibrosis quística. Anales med, 61(4): 305–309 https://www.medigraphic.com/pdfs/abc/bc-2016/bc164m.pdf

Turcios N. (2020). Cystic fibrosis lung disease: an overview. Respir Care, 65(2):233–251. https://doi.org/10.4187/respcare.06697

Yesudhas D., Srivastava A., & Gromiha M. (2021). COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection, 49(2): 199–213. https://doi.org/10.1007/s15010-020-01516-2

Yu E. & Sharma S. (2021). Cystic Fibrosis. NCBI StatPearls, NCBI https://www.ncbi.nlm.nih.gov/books/NBK493206/

Downloads

Published

2024-10-30

How to Cite

Orozco, L., & Martínez-Hernández, A. (2024). Cystic Fibrosis and the SARS-CoV-2 Virus: A Review. Mesoamerican Journal of Research, 4(5), 1–5. https://doi.org/10.31644/RMI.V4N5.2024.A11